Protein arginine methyltransferase 5 (PRMT5) messenger RNA (PRMT5 mRNA)

Protein Arginine Methyltransferase 5 (PRMT5) mRNA is the messenger RNA transcript that encodes the PRMT5 enzyme, a critical type II methyltransferase responsible for the symmetric dimethylation of arginine residues on histone and non-histone proteins (UniProt). PRMT5 is a key regulator of diverse cellular processes, including RNA splicing, gene transcription, signal transduction, and cell cycle progression (NIH). In many human cancers, such as mantle cell lymphoma, glioblastoma, and various solid tumors, PRMT5 mRNA is significantly overexpressed, driving oncogenic pathways and promoting cell survival (PubMed). Therapeutic strategies targeting PRMT5 mRNA include the use of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to induce transcript degradation or block translation, thereby depleting the PRMT5 protein (NIH). Additionally, the PRMT5 pathway is a major focus of synthetic lethality research, particularly in tumors with MTAP (methylthioadenosine phosphorylase) deletion, where cells become hypersensitive to PRMT5 inhibition (PubMed). While most current clinical-stage drugs, such as GSK3326595 and JNJ-64619178, are small molecules targeting the PRMT5 protein, the mRNA remains a vital target for knockdown-based therapeutic modalities and research into gene regulation (NIH). Monitoring PRMT5 mRNA levels and downstream biomarkers like symmetric dimethylarginine (SDMA) is essential for assessing therapeutic efficacy and patient selection (PubMed).

Other names

SKB1JBP1HRMT5L1IBP72Protein arginine N-methyltransferase 5 mRNA

RNA interference, antisense inhibition, and translation inhibition leading to depletion of the PRMT5 enzyme.